Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsOscar Health Albendazole Prior Auth | OpenPayer
    Ask Trek AI about this page
    CurrentOscar HealthPolicy PG101

    Albendazole (Albenza) Coverage and Prior Authorization

    Customize your policy alerts

    Sign up for Oscar Health Policy PG101 alerts

    Get alerted when Policy PG101 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs Oscar Health medical necessity, prior authorization, initial approval, and reauthorization requirements for albendazole (Albenza) used to treat specified parasitic infections.

    Policy Summary
    PayerOscar Health
    PolicyAlbendazole (Albenza) Coverage and Prior Authorization
    Policy CodePolicy PG101
    Change TypeNo material change
    Effective DateN/A
    Last ReviewJan 4, 202747d
    Next Review DateN/A
    Key ActionSubmit up-to-date chart notes, relevant test results, and/or relevant imaging reports supporting the diagnosis.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    19Covered infection diagnoses
    6 monthsMaximum approval for select diagnoses
    1 monthMaximum approval for other diagnoses
    2Generic manufacturers required before brand Albenza
    Case-by-caseRenewal review

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Not coveredOther uses

    Coverage Criteria

    Initial therapy for covered infections

    Covered when all of the following are met:

    Initial medical necessity requirements

    • Covered infection pathway

      • Documented covered infection: The member has a documented diagnosis of ascariasis, baylisascariasis, capillariasis, cutaneous larva migrans, cystic hydatid disease of the liver, lung, or peritoneum, eosinophilic enterocolitis, filariasis, gnathostomiasis, gongylonemiasis, intestinal hookworm infection, loiasis, microsporidiosis, oesophagostomiasis, parenchymal neurocysticercosis with active lesions, strongyloidiasis, toxocariasis, trematode infection, trichinellosis, or trichuriasis.One diagnosis from the listed group

        The diagnosis must be caused by the organisms specified in the policy.

      • Enterobiasis or trichostrongyliasis pathway: The member has a documented diagnosis of enterobiasis caused by Enterobius vermicularis or trichostrongyliasis caused by Trichostrongylus and is unable to use or has tried and failed over-the-counter pyrantel pamoate.
      • Giardiasis pathway

        • Age-based preferred alternatives: If the member is age 17 or younger, the member is unable to use or has tried and failed one of metronidazole, nitazoxanide, or tinidazole. If the member is age 18 or older, the member is unable to use or has tried and failed all of metronidazole, nitazoxanide, and tinidazole.Age 17 or younger: one alternative; age 18 or older: all three alternatives
    • Baseline testing: Before initiation of treatment, clinically appropriate baseline testing has been completed, including a complete blood count, pregnancy testing in a woman of reproductive potential, and an ophthalmic examination for retinal lesions before therapy for neurocysticercosis.As clinically appropriate
    • Brand requirement: If the request is for brand Albenza, the member is unable to use or has tried and failed generic albendazole from two manufacturers when available. This requirement does not apply to requests that are not for brand Albenza.Two manufacturers when available
    • Dose and frequency: Albendazole is prescribed at a dose and frequency within FDA-approved labeling or supported by compendia or evidence-based published dosing guidelines for the requested indication.FDA-approved labeling, compendia, or evidence-based published dosing guidelines

    Subsequent or continuation therapy

    Covered when the renewal documentation supports continued medical necessity:

    Continuation therapy

    • Current clinical documentation: Provide current clinical documentation supporting the need for continued therapy.
    • Treatment response: Provide the member's response to the previous course of treatment.
    • Continuation plan: Provide the planned duration of continued treatment.

    Other uses

    Not covered under this guideline:

    Other use: Albendazole (Albenza) for any use other than the specified covered indications is considered experimental, investigational, or unproven.Any other use

    Albendazole (Albenza) for any use other than the specified covered indications is considered experimental, investigational, or unproven under this policy.

    Provider Actions and Request Requirements

    Prior Authorization

    Initial Prior Authorization Requirements

    Prior authorization is required for initial therapy. Submit documentation showing a policy-listed infection, clinically appropriate pretreatment testing, and dosing that follows FDA-approved labeling or is supported by compendia or evidence-based published guidelines. For brand Albenza, also document inability to use or trial and failure of generic albendazole from two manufacturers, when available.

    • Covered infections include ascariasis; baylisascariasis; capillariasis; cutaneous larva migrans; cystic hydatid disease; eosinophilic enterocolitis; filariasis; gnathostomiasis; gongylonemiasis; intestinal hookworm infection; loiasis; microsporidiosis; oesophagostomiasis; parenchymal neurocysticercosis; strongyloidiasis; toxocariasis; trematode infections; trichinellosis; and trichuriasis.
    • For enterobiasis or trichostrongyliasis, document both the diagnosis and inability to use or trial and failure of OTC pyrantel pamoate.
    • For giardiasis, document both the diagnosis and the required age-specific preferred-alternative therapy history.
    • Complete clinically appropriate baseline testing before treatment, including CBC, pregnancy testing for a woman of reproductive potential, and an ophthalmic examination for retinal lesions before therapy for neurocysticercosis.
    • Requested dose and frequency must be within FDA-approved labeling or supported by compendia or evidence-based published dosing guidelines.

    Background

    Albendazole is a broad-spectrum antihelminthic medication used to treat various parasitic worm infections. This policy addresses oral albendazole, including generic albendazole and brand Albenza, for specified infections such as intestinal helminth infections, cystic hydatid disease, parenchymal neurocysticercosis, and selected protozoal or tissue-parasite infections. Dose and treatment duration depend on the infection being treated.

    Definitions

    Definitions
    AntihelminthicsA class of antiparasitic drugs that target and help eliminate parasitic worms and other internal parasites from the body.
    Definitions
    DocumentationWritten information, including up-to-date chart notes, relevant test results, relevant imaging reports supporting diagnoses, and prescription claims records or receipts supporting prior trials of formulary alternatives.
    Definitions
    HelminthsA group of parasitic worms.
    Definitions

    Albendazole Initial Therapy

    Albendazole initial therapy

    Initial therapy is covered when all of the following requirements are met:

    Initial albendazole therapy

    • Covered infection pathway

      • Documented covered infection: The member has a documented diagnosis of ascariasis, baylisascariasis, capillariasis, cutaneous larva migrans, cystic hydatid disease of the liver, lung, or peritoneum, eosinophilic enterocolitis, filariasis, gnathostomiasis, gongylonemiasis, intestinal hookworm infection, loiasis, microsporidiosis, oesophagostomiasis, parenchymal neurocysticercosis with active lesions, strongyloidiasis, toxocariasis, trematode infection, trichinellosis, or trichuriasis.One diagnosis from the listed group

        The diagnosis must be caused by the organisms specified in the policy.

      • Enterobiasis or trichostrongyliasis pathway: The member has a documented diagnosis of enterobiasis caused by Enterobius vermicularis or trichostrongyliasis caused by Trichostrongylus and is unable to use or has tried and failed over-the-counter pyrantel pamoate.

    Albendazole Continuation Therapy

    Albendazole continuation therapy

    Renewals require case-by-case review and documentation of continued medical necessity:

    Continuation requirements: Provide current clinical documentation supporting continued therapy, the member's response to the previous course of treatment, and a plan for the duration of continued treatment.All three elements

    All prior authorization renewals are reviewed case by case. Authorization may be extended based on the submitted documentation, current treatment guidelines, and individual member needs.

    Required Alternative Therapy

    ConditionRequired prior therapyCoverage status
    Enterobiasis caused by Enterobius vermicularis or trichostrongyliasis caused by TrichostrongylusMember is unable to use, or has tried and failed, over-the-counter pyrantel pamoate before albendazole.Albendazole covered when requirement is met.
    Member ageRequired prior therapyCoverage status
    17 years or youngerMember is unable to use, or has tried and failed, one preferred alternative: metronidazole, nitazoxanide, or tinidazole.Albendazole covered when requirement is met.
    18 years or olderMember is unable to use, or has tried and failed, all three preferred alternatives: metronidazole, nitazoxanide, and tinidazole.Albendazole covered when requirement is met.
    Requested productRequired prior therapyCoverage status
    Brand AlbenzaMember is unable to use, or has tried and failed, generic albendazole from two manufacturers when available.Brand Albenza covered when requirement is met.

    Approval Duration Limits

    Quantity Limits
    Medicationalbendazole (Albenza)
    Cystic hydatid disease or parenchymal neurocysticercosisApproval may be granted for up to 6 months.
    All other diagnosesApproval may be granted for up to 1 month.
    Policy Summary
    PayerOscar Health
    PolicyAlbendazole (Albenza) Coverage and Prior Authorization
    Policy CodePolicy PG101
    Change TypeNo material change
    Effective DateN/A
    Last ReviewJan 4, 202747d
    Next Review DateN/A
    Key ActionSubmit up-to-date chart notes, relevant test results, and/or relevant imaging reports supporting the diagnosis.
    SourceLink
    On This Page
    Coverage CriteriaProvider Actions and Request RequirementsBackgroundDefinitionsAlbendazole Initial TherapyAlbendazole Continuation TherapyRequired Alternative TherapyApproval Duration Limits
    Note

    Initial Approval Duration

    When initial criteria are met, approval is limited by diagnosis and may be extended only when supported by submitted documentation, current treatment guidelines, and individual member needs.

    • Up to 6 months: cystic hydatid disease due to Echinococcus granulosus or parenchymal neurocysticercosis due to Taenia solium.
    • Up to 1 month: all other covered diagnoses.
    Documentation Required

    Reauthorization Review

    Renewals are reviewed case by case to determine whether continuation remains medically necessary and supported by current treatment guidelines. Extensions depend on the documentation provided and individual member needs.

    • Provide current clinical documentation supporting continued therapy.
    • Document the member’s response to the previous course of treatment.
    • Provide the planned duration of continued treatment.
    Step Therapy

    Pyrantel Pamoate Requirement

    For enterobiasis caused by Enterobius vermicularis or trichostrongyliasis caused by Trichostrongylus, document that the member is unable to use, or has tried and failed, OTC pyrantel pamoate.

    • Both the covered diagnosis and the OTC pyrantel pamoate requirement must be addressed in the request.
    Step Therapy

    Giardiasis Preferred Alternatives

    For giardiasis caused by Giardia duodenalis, document the required inability to use or trial and failure of preferred alternatives according to age.

    • Members 17 years of age or younger: inability to use, or trial and failure of one preferred alternative—metronidazole, nitazoxanide, or tinidazole.
    • Members 18 years of age and older: inability to use, or trial and failure of all preferred alternatives—metronidazole, nitazoxanide, and tinidazole.
    Step Therapy

    Generic Albendazole Trial

    When requesting brand Albenza, establish that the member is unable to use, or has tried and failed, generic albendazole from two manufacturers, when available.

    • Document the generic trials or the specific reason generic albendazole from two manufacturers cannot be used.
    Documentation Required

    Clinical and Alternative-Therapy Documentation

    Submit documentation sufficient to support the diagnosis and required alternative-therapy history.

    • Up-to-date chart notes and relevant test results and/or imaging reports supporting the diagnosis.
    • Prescription claims records and/or prescription receipts supporting prior trials of formulary alternatives.
    Documentation Required

    Baseline Testing

    Complete and submit clinically appropriate pretreatment testing before initiation of therapy.

    • Complete blood count (CBC).
    • Pregnancy test for a woman of reproductive potential, when applicable.
    • Ophthalmic examination for retinal lesions before initiating therapy for neurocysticercosis, when applicable.
    Documentation Required

    Renewal Documentation

    For reauthorization, provide current evidence that continued albendazole therapy remains necessary and that the member’s prior treatment response supports renewal.

    • Current clinical documentation supporting continued treatment.
    • Response to the previous course of treatment.
    • Plan and expected duration for continued treatment.
    Denial Risk

    Unlisted or Unproven Indication

    Denial risk: albendazole (Albenza) is considered experimental, investigational, or unproven when requested for an infection or other use not listed in the policy criteria.

    • Confirm that the requested infection appears among the policy-covered diagnoses.
    • Requests for any other use may be denied as experimental, investigational, or unproven.
    Denial Risk

    Required Alternative Therapy Not Met

    Denial risk: requests may not meet criteria when the required alternative therapy has not been addressed.

    • For enterobiasis or trichostrongyliasis, document inability to use or trial and failure of OTC pyrantel pamoate.
    • For giardiasis in members 17 or younger, document inability to use or trial and failure of one of metronidazole, nitazoxanide, or tinidazole.
    • For giardiasis in members 18 or older, document inability to use or trial and failure of metronidazole, nitazoxanide, and tinidazole.
    Denial Risk

    Brand Requested Without Generic Trials

    Denial risk: a brand Albenza request may not meet criteria when generic albendazole can be used or the required generic trials are not documented.

    • Establish inability to use, or trial and failure of generic albendazole from two manufacturers, when available.
    Denial Risk

    Missing Baseline Testing or Unsupported Dosing

    Denial risk: requests may be denied when required baseline testing is incomplete or the requested dose and frequency are not supported for the indication.

    • Submit clinically appropriate CBC, pregnancy testing when applicable, and ophthalmic examination before neurocysticercosis therapy when applicable.
    • Ensure the requested dose and frequency follow FDA-approved labeling or are supported by compendia or evidence-based published dosing guidelines.
    MicrotubulesCylindrical structures within cellular cytoplasm that provide structure and shape to cells and are involved in cell division and intracellular transport.
  1. Giardiasis pathway

    • Age-based preferred alternatives: If the member is age 17 or younger, the member is unable to use or has tried and failed one of metronidazole, nitazoxanide, or tinidazole. If the member is age 18 or older, the member is unable to use or has tried and failed all of metronidazole, nitazoxanide, and tinidazole.Age 17 or younger: one alternative; age 18 or older: all three alternatives
  2. Baseline testing: Before initiation of treatment, clinically appropriate baseline testing has been completed, including a complete blood count, pregnancy testing in a woman of reproductive potential, and an ophthalmic examination for retinal lesions before therapy for neurocysticercosis.As clinically appropriate
  3. Brand requirement: If the request is for brand Albenza, the member is unable to use or has tried and failed generic albendazole from two manufacturers when available. This requirement does not apply to requests that are not for brand Albenza.Two manufacturers when available
  4. Dose and frequency: Albendazole is prescribed at a dose and frequency within FDA-approved labeling or supported by compendia or evidence-based published dosing guidelines for the requested indication.FDA-approved labeling, compendia, or evidence-based published dosing guidelines